Aardvark Therapeutics (AARD) vs Rallybio (RLYB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Rallybio (RLYB) has outperformed Aardvark Therapeutics (AARD) over the past year, gaining 297.5% versus a loss of 69.6%. Aardvark Therapeutics is the larger company by market cap ($97.4 million vs $89.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | RLYB |
|---|---|---|
| Share price | $4.45 | $16.79 |
| Market cap | $97.39M | $89.20M |
| 1-day change | -6.51% | -1.35% |
| YTD return | -66.10% | +205.94% |
| 1-year return | -69.58% | +297.49% |
| 5-year return | — | -87.07% |
| P/E ratio (TTM) | — | 2.10 |
| EPS (TTM) | $-3.21 | $8.01 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.60 | $17.57 |
| 52-week low | $3.35 | $3.67 |
| Distance from 52-week high | -73.19% | -4.46% |
| Analyst consensus | buy | — |
| Avg. price target upside | +149.66% | — |
| Average volume | 146.39K | 21.01K |
| Shares outstanding | 21.88M | 5.31M |
| Employees | 28 | 7 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RLYB has outperformed AARD by 367.1 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Rallybio
RLYB stock →Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload.
Health Care · Biotechnology: Pharmaceutical Preparations · 7 employees
AARD vs RLYB FAQ
Which is bigger, Aardvark Therapeutics or Rallybio?
Aardvark Therapeutics (AARD) is larger, with a market capitalization of $97.39M compared with $89.20M for Rallybio (RLYB).
Which stock has performed better over the past year, AARD or RLYB?
RLYB returned +297.49% over the past 12 months, compared with -69.58% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Rallybio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.